Palatin Technologies (PTN) Assets Average (2011 - 2026)
Palatin Technologies' (PTN) quarterly Assets Average came in at $15.6 million in Q1 2026, up 287.55% on a YoY basis from $4.0 million in Q1 2025, and up 17.37% quarter-over-quarter from $13.3 million in Q4 2025.
Analysis
Palatin Technologies (PTN) Assets Average (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Assets Average for 14 consecutive years, with $15.6 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Assets Average rose 287.55% year-over-year to $15.6 million; the trailing twelve-month figure through Mar 2026 stood at $15.6 million (up 287.55% YoY), and the FY2025 full-year result was $7.0 million, down 51.16% from the prior year.
- Assets Average grew to $15.6 million in Q1 2026 per PTN's latest filing, from $13.3 million in the prior quarter.
- Across five years, Assets Average topped out at $48.4 million in Q1 2022 and bottomed at $3.5 million in Q2 2025.
- Historically, Assets Average has averaged $17.9 million across 5 years, with a median of $13.3 million in 2025.
- The sharpest annual moves came in 2024 and 2026: Assets Average tumbled 68.85% in 2024, then soared 287.55% in 2026.
- Over 5 years, Assets Average stood at $29.8 million in 2022, then plunged by 58.4% to $12.4 million in 2023, then sank by 68.85% to $3.9 million in 2024, then surged by 243.58% to $13.3 million in 2025, then rose by 17.37% to $15.6 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $15.6 million, $13.3 million, and $5.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 5.51 Bn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | 15.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 15.58 Mn |
| Dec 31, 2025 | 13.27 Mn |
| Sep 30, 2025 | 5.94 Mn |
| Jun 30, 2025 | 3.50 Mn |
| Mar 31, 2025 | 4.02 Mn |
| Dec 31, 2024 | 3.86 Mn |
| Sep 30, 2024 | 7.08 Mn |
| Jun 30, 2024 | 11.07 Mn |
| Mar 31, 2024 | 12.48 Mn |
| Dec 31, 2023 | 12.40 Mn |
| Sep 30, 2023 | 14.59 Mn |
| Jun 30, 2023 | 21.77 Mn |
| Mar 31, 2023 | 28.79 Mn |
| Dec 31, 2022 | 29.81 Mn |
| Sep 30, 2022 | 31.86 Mn |
| Jun 30, 2022 | 39.94 Mn |
| Mar 31, 2022 | 48.41 Mn |
| Dec 31, 2021 | 56.36 Mn |
| Sep 30, 2021 | 63.51 Mn |
| Jun 30, 2021 | 74.08 Mn |